Home > ATLAS Project Research Members
ATLAS Project Research Members
National Cancer Center Hospital (Tokyo, Japan)
YAZAKI Shu (Depertment of Medical Oncology)
YAZAKI Shu MD
Dr. YAZAKI's story
After receiving my medical degree from Nihon University School of Medicine in 2012, I completed my residency in Internal Medicine and fellowship in Medical Oncology at St. Luke's International Hospital. I have also completed training in National Cancer Center Hospital, focusing on breast, gynecologic, sarcoma, rare tumor, and Phase I clinical trials. I am currently a physician-scientist in the Department of International Clinical Development, International Translational Research Section. I have a research activity in the Division of Genome Biology, in parallel of patient care.
Research interests
My research interests include identifying novel drug targets and discovering biomarkers based on multi-omics data.
Professional Experiences
- 2021-current Staff Physician, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan
- 2019-2021 Chief Resident, Department of Breast and Medical Oncology, National Cancer Center Hospital, Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan
- 2018 Japan Medical Exchange Program; Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX
- 2016-2019 Clinical Fellow, Division of Medical Oncology, St. Luke’s International Hospital
Selected publications
- Yazaki S, Yoshida T, Kojima Y, et al. Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan. JAMA Oncol. Published online May 28, 2021. doi:10.1001/jamaoncol.2021.2159
- Yazaki S, Yamauchi T, Higashi T. High hepatitis B virus screening rate among patients receiving systemic anticancer treatment in Japan. Int J Clin Oncol. 2020;25(7):1327-1333.
- Yazaki S, Hashimoto J, Ogita S, Nakano E, Suzuki K, Yamauchi T. Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective study. Anti-cancer drugs. 2020;31(9):973-8.
- Watanuki R, Shimomura A, Yazaki S, Noda-Narita S, Sumiyoshi-Okuma H, Nishikawa T, et al. Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment. Medicine. 2020;99(38):e22331
- Yokoe T, Kurozumi S, Nozawa K, Ozaki Y, Maeda T, Yazaki S, et al. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B). Breast cancer. 2021;28(3):581-91.
- Yazaki S, Kojima Y, Yoshida H, et al. Abstract 361: Mesothelin expression varies by histological type in patients with cervical cancer and is reduced in metastatic tumors. Cancer Research. 2021;81(13 Supplement):361-
- Takamizawa S, Yazaki S, Kojima Y, et al. Abstract 657: Folate receptor alpha expression is associated with poor prognosis in patients with cervical cancer. Cancer Research. 2021;81(13 Supplement):657-.
Link
Photo
